Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
3.67(c) 3.7(c) 3.74(c) 3.83(c) 3.79(c) Last
508 169 595 671 466 165 750 765 291 138 Volume
-1.87% +0.82% +1.08% +2.41% -1.04% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 188 M - -
Net income 2021 18,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 35,9x
Yield 2021 -
Sales 2022 233 M - -
Net income 2022 38,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 17,6x
Yield 2022 -
Capitalization 644 M 644 M -
Capi. / Sales 2021 3,43x
Capi. / Sales 2022 2,76x
Nbr of Employees 185
Free-Float 97,9%
More Financials
Company
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable... 
More about the company
Ratings of Antares Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ANTARES PHARMA, INC.
09/08ANTARES PHARMA : to Participate in the H.C. Wainright 23rd Annual Global Investment Confer..
PU
09/08Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conf..
GL
08/18ANTARES PHARMA, INC. : Regulation FD Disclosure (form 8-K)
AQ
08/06Antares pharma reports second quarter 2021 financial and operating resultsewing
AQ
08/05ANTARES PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
08/05ANTARES PHARMA, INC. : Results of Operations and Financial Condition, Financial Statements..
AQ
08/05Antares Pharma, Inc. Reaffirms Revenue Guidance for the Full Year 2021
CI
08/05ANTARES PHARMA : Q2 Earnings Snapshot
AQ
08/05ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Reports Q2 Revenue $45M, vs. Street ..
MT
08/05ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Posts Q2 EPS $0.03, vs. Street Est o..
MT
08/05ANTARES PHARMA : Reports Second Quarter 2021 Financial and Operating Results
AQ
08/05Antares Pharma, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
07/28Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
GL
07/22ANTARES PHARMA : Gets US FDA OK to Start Trial of ATRS-1902 in Acute Adrenal Insufficiency
MT
07/22ANTARES PHARMA : Announces FDA Acceptance of IND Application for ATRS 1902 For Adrenal Cri..
PU
More news
News in other languages on ANTARES PHARMA, INC.
06/28Idorsia lance une étude clinique avancée contre l'infarctus
06/28GlobeNewswire/Idorsia initiates the Phase 3 -2-
06/28GlobeNewswire/Idorsia initiates the Phase 3 registration study with selatogrel for the ..
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations
Chart ANTARES PHARMA, INC.
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | ATRS | US0366421065 | MarketScreener
Technical analysis trends ANTARES PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,79 $
Average target price 6,64 $
Spread / Average Target 75,3%
EPS Revisions
Managers and Directors
Robert F. Apple President, Chief Executive Officer & Director
Fred M. Powell Chief Financial Officer & Executive Vice President
Leonard S. Jacob Chairman
Jonathan S. Jaffe Vice President-Clinical & Medical Affairs
Peter C. Richardson Chief Medical Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
ANTARES PHARMA, INC.-5.01%644
ABBOTT LABORATORIES13.59%220 485
MEDTRONIC PLC11.00%174 982
BECTON, DICKINSON AND COMPANY1.18%72 711
HOYA CORPORATION30.69%62 143
ALIGN TECHNOLOGY, INC.35.72%57 302